DK1032672T3 - DNA19355-polypeptid, en tumornekrosefaktor-homolog - Google Patents

DNA19355-polypeptid, en tumornekrosefaktor-homolog

Info

Publication number
DK1032672T3
DK1032672T3 DK98958067T DK98958067T DK1032672T3 DK 1032672 T3 DK1032672 T3 DK 1032672T3 DK 98958067 T DK98958067 T DK 98958067T DK 98958067 T DK98958067 T DK 98958067T DK 1032672 T3 DK1032672 T3 DK 1032672T3
Authority
DK
Denmark
Prior art keywords
dna19355
necrosis factor
tumor necrosis
dna19355 polypeptide
factor homologue
Prior art date
Application number
DK98958067T
Other languages
Danish (da)
English (en)
Inventor
Austin L Gurney
Scot A Marsters
Paul J Godowski
Avi J Ashkenazi
Robert Pitti
Kevin P Baker
Melanie R Mark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1032672T3 publication Critical patent/DK1032672T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98958067T 1997-11-18 1998-11-18 DNA19355-polypeptid, en tumornekrosefaktor-homolog DK1032672T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6563597P 1997-11-18 1997-11-18
US6966197P 1997-12-12 1997-12-12
PCT/US1998/024621 WO1999025834A1 (fr) 1997-11-18 1998-11-18 Polypeptide adn19355, homologue du facteur de necrose des tumeurs

Publications (1)

Publication Number Publication Date
DK1032672T3 true DK1032672T3 (da) 2009-04-27

Family

ID=26745805

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98958067T DK1032672T3 (da) 1997-11-18 1998-11-18 DNA19355-polypeptid, en tumornekrosefaktor-homolog

Country Status (12)

Country Link
US (4) US20020146389A1 (fr)
EP (1) EP1032672B1 (fr)
JP (2) JP4485049B2 (fr)
AT (1) ATE419357T1 (fr)
AU (1) AU760010B2 (fr)
CA (1) CA2308365A1 (fr)
DE (1) DE69840413D1 (fr)
DK (1) DK1032672T3 (fr)
ES (1) ES2320285T3 (fr)
IL (1) IL135911A0 (fr)
PT (1) PT1032672E (fr)
WO (1) WO1999025834A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
WO2001040464A1 (fr) * 1999-11-30 2001-06-07 Genentech, Inc. Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation
DK1212417T3 (da) * 1999-06-02 2008-09-01 Genentech Inc Fremmelse eller inhibering af angiogenese og vaskularisering
PT1196186E (pt) * 1999-07-12 2008-02-14 Genentech Inc Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US20030133936A1 (en) * 2001-07-12 2003-07-17 Byrne Michael Chapman CD25markers and uses thereof
AU2002366433A1 (en) * 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
EP1495756A4 (fr) * 2002-04-08 2009-10-28 Takeda Pharmaceutical Agent therapeutique pour la prevention d'etat septique grave
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20050048054A1 (en) * 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
WO2005055808A2 (fr) * 2003-12-02 2005-06-23 Genzyme Corporation Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
US20070065889A1 (en) * 2004-12-02 2007-03-22 Roberts Bruce L Compositions and methods to diagnose and treat lung cancer
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP6812364B2 (ja) 2015-06-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌診断用抗ｇｉｔｒ抗体
CA3005855A1 (fr) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Anticorps diriges contre un recepteur du facteur de necrose tumorale induit par glucocorticoides (gitr) et leurs utilisations
IL263273B2 (en) 2016-06-10 2025-10-01 Regeneron Pharma Antibodies against GITR and their uses
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
WO2021178814A1 (fr) 2020-03-06 2021-09-10 Regeneron Pharmaceuticals, Inc. Anticorps anti-gitr et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
KR100510234B1 (ko) * 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
CA2264200A1 (fr) * 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Endokine alpha humaine
US5998171A (en) * 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha

Also Published As

Publication number Publication date
AU1418099A (en) 1999-06-07
US20070072263A1 (en) 2007-03-29
JP2010088448A (ja) 2010-04-22
AU760010B2 (en) 2003-05-08
ES2320285T3 (es) 2009-05-20
EP1032672A1 (fr) 2000-09-06
PT1032672E (pt) 2009-04-02
US20060216270A1 (en) 2006-09-28
ATE419357T1 (de) 2009-01-15
IL135911A0 (en) 2001-05-20
US20020146389A1 (en) 2002-10-10
CA2308365A1 (fr) 1999-05-27
US20040234498A1 (en) 2004-11-25
JP4485049B2 (ja) 2010-06-16
JP2001523459A (ja) 2001-11-27
EP1032672B1 (fr) 2008-12-31
DE69840413D1 (de) 2009-02-12
WO1999025834A1 (fr) 1999-05-27

Similar Documents

Publication Publication Date Title
DE69840413D1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69535719D1 (de) Fas-antigenbindender ligand
TW428026B (en) Bifunctional protein, preparation and use
FI101720B1 (fi) Synteettisen DNA:n konstruointi ja sen käyttö suurten polypeptidien synteesissä
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
EP0575546A4 (en) Prad1 cyclin and its cdna
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE68905633D1 (de) Markierer der t-zelle aktivierung.
BG100771A (bg) Хематопоетичен протеин и материали и методи за неговото получаване
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
DE69737747D1 (de) Apo-2 ligand
PT770088E (pt) Nova citoquina designada lerk-5
NL990034I2 (nl) DNA dat codeert voor humane tumor necrosis faktor en humane tumor necrosis faktor polypeptide.
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
DK0804558T3 (da) Tripeptidylaminopeptidase
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ATE424459T1 (de) Apo-3 ligand
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen